Strategic Fit

Apollo Hospitals Enterprise Ltd has completed the acquisition of 85,00,000 equity shares of Apollo Gleneagles PET-CT Pvt Ltd (AGPCL) from Parkway Healthcare (Mauritius) Pte Ltd, making AGPCL a wholly-owned subsidiary. The acquisition is a part of Apollo’s long-term strategy to deepen its presence in advanced diagnostic and imaging services, a segment witnessing strong growth due to rising demand for precision healthcare and early disease detection.

Deal Structure

Under the transaction finalized on October 3, 2025, Apollo Hospitals purchased the entire stake previously held by Parkway Healthcare. The move consolidates ownership of AGPCL under Apollo Hospitals, enabling seamless operational control and faster decision-making in diagnostic expansion. Financial terms of the deal were not disclosed publicly.

Competitive Landscape

The acquisition enhances Apollo’s diagnostic ecosystem, positioning it strongly against emerging players such as SRL Diagnostics, Metropolis, and Dr. Lal PathLabs. With India’s diagnostics market expected to grow at a CAGR of over 10% through 2030, Apollo’s control of AGPCL adds significant strength to its integrated healthcare model, combining hospitals, clinics, and advanced diagnostic centers under one brand.

Market Reaction

Market experts view this acquisition as a strategic consolidation move that will improve Apollo’s margins and strengthen patient retention. While the share price showed limited immediate movement, the deal reinforces investor confidence in Apollo’s long-term growth trajectory within the high-margin diagnostics segment.

Final Word

By taking full ownership of AGPCL, Apollo Hospitals has secured a stronger foothold in the rapidly expanding diagnostic imaging space. This acquisition is expected to yield operational synergies, enhance clinical integration, and contribute to Apollo’s goal of delivering comprehensive, technology-driven healthcare solutions across India.